Race Oncology (ASX:RAC) signed an AU$8.6 million contract with the Contract Research Organization, George Clinical International, to support the RAC-010 Phase 1 trial of its RC220 bisantrene drug candidate in combination with doxorubicin in adult patients with advanced tumors across sites in Australia, Hong Kong, and South Korea, according to a Wednesday Australian bourse filing.
This covers all outsourced trial-related services, investigator grants, and pass-through costs for up to 53 patients for the dose escalation and dose expansion stages of the trial.
After an interim analysis, the optimal dosage of RC220 bisantrene in combination with doxorubicin will be evaluated in further patients for safety, tolerability, and preliminary cardioprotective and anti-cancer efficacy properties.
Its shares rose 3% on market close on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.